Abstract
Prions are renowned for their role in neurodegenerative diseases in humans and animals. These are manifested as transmissible spongiform encephalopathies (TSEs) that result from the conversion of the normal glycosylphosphatidylinositol (GPI) anchored cellular prion protein (PrPc) to a misfolded, aggregated and pathogenic form, prion protein scrapie (PrPSc) via a post-translational process followed by the accumulation of PrP>Sc within the central nervous system.
New research in this area has demonstrated that PrP is over-expressed in a variety of cancers including gastric, pancreatic and breast cancers, affecting the growth and invasiveness of these cancers as well as playing an important role in the acquisition of multi-drug resistant (MDR) gastric cancer. Prion-like doppel protein (Dpl), sharing 25% amino acid sequence homology to PrP and whose function remains elusive, has also been shown to exhibit a high level of expression in a number of cancers including acute myeloid leukemia’s, myelodysplastic syndromes, gastric adenocarcinoma, anaplastic meningioma and astrocytomas. Furthermore, the tumour suppressor protein, p53, already known for its involvement in cancer development, has recently been shown to display prion-like tendencies.
This review provides an overview of prions and prion-like proteins in mammals discussing their structure, function and role in cell function and disease. Furthermore, current research progress on the role of prion/prion-like proteins in the development, progression, and drug resistance of various cancers will be summarized. Potential implications for future development of new therapeutic treatments targeting prion and prion-like proteins will be discussed.
Keywords: Epigenetic, PRND, PRNP, protein misfolding, tumour marker.
Current Cancer Drug Targets
Title:Significance of Prion and Prion-Like Proteins in Cancer Development, Progression and Multi-Drug Resistance
Volume: 13 Issue: 8
Author(s): Caroline Hinton, Helma Antony, Saeed M. Hashimi, Alan Munn and Ming Q. Wei
Affiliation:
Keywords: Epigenetic, PRND, PRNP, protein misfolding, tumour marker.
Abstract: Prions are renowned for their role in neurodegenerative diseases in humans and animals. These are manifested as transmissible spongiform encephalopathies (TSEs) that result from the conversion of the normal glycosylphosphatidylinositol (GPI) anchored cellular prion protein (PrPc) to a misfolded, aggregated and pathogenic form, prion protein scrapie (PrPSc) via a post-translational process followed by the accumulation of PrP>Sc within the central nervous system.
New research in this area has demonstrated that PrP is over-expressed in a variety of cancers including gastric, pancreatic and breast cancers, affecting the growth and invasiveness of these cancers as well as playing an important role in the acquisition of multi-drug resistant (MDR) gastric cancer. Prion-like doppel protein (Dpl), sharing 25% amino acid sequence homology to PrP and whose function remains elusive, has also been shown to exhibit a high level of expression in a number of cancers including acute myeloid leukemia’s, myelodysplastic syndromes, gastric adenocarcinoma, anaplastic meningioma and astrocytomas. Furthermore, the tumour suppressor protein, p53, already known for its involvement in cancer development, has recently been shown to display prion-like tendencies.
This review provides an overview of prions and prion-like proteins in mammals discussing their structure, function and role in cell function and disease. Furthermore, current research progress on the role of prion/prion-like proteins in the development, progression, and drug resistance of various cancers will be summarized. Potential implications for future development of new therapeutic treatments targeting prion and prion-like proteins will be discussed.
Export Options
About this article
Cite this article as:
Hinton Caroline, Antony Helma, Hashimi M. Saeed, Munn Alan and Wei Q. Ming, Significance of Prion and Prion-Like Proteins in Cancer Development, Progression and Multi-Drug Resistance, Current Cancer Drug Targets 2013; 13 (8) . https://dx.doi.org/10.2174/156800961131300092
DOI https://dx.doi.org/10.2174/156800961131300092 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Sirtuins: Multifaceted Drug Targets
Current Molecular Medicine Evaluating Intestinal Permeability by Measuring Plasma Endotoxin and Diamine Oxidase in Children with Acute Lymphoblastic Leukemia Treated with High-dose Methotrexate
Anti-Cancer Agents in Medicinal Chemistry Evaluation of Antitumor Activity and Hepatoprotective Effect of Mitomycin C Solubilized in Chamomile Oil Nanoemulsion
Anti-Cancer Agents in Medicinal Chemistry Cell-penetrating Peptide-mediated Nanovaccine Delivery
Current Drug Targets Nanostructured Cubosomes as a Platform for Oral Drug Delivery
Current Pharmaceutical Biotechnology Emerging Indications for Statins: A Pluripotent Family of Agents with Several Potential Applications
Current Pharmaceutical Design Toxicological Profile of Therapeutic Nanodelivery Systems
Current Drug Metabolism Targeting Calcium Channels to Block Tumor Vascularization
Recent Patents on Anti-Cancer Drug Discovery Pharmacogenetics of Thiopurines in Inflammatory Bowel Disease
Current Pharmaceutical Design New Antimicrobial Frontiers
Mini-Reviews in Medicinal Chemistry Design, Preparation and Characterization of Modular Squalene-based Nanosystems for Controlled Drug Release
Current Topics in Medicinal Chemistry Sensitive and Selective Immunofluorescence Assay for CA15-3 Detection Using Fluorescein Derivative A10254
Protein & Peptide Letters Receptor for AGEs (RAGE) as Mediator of NF-kB Pathway Activation in Neuroinflammation and Oxidative Stress
CNS & Neurological Disorders - Drug Targets Subject Index To Volume 6
Current Topics in Medicinal Chemistry Nutraceuticals and "Repurposed" Drugs of Phytochemical Origin in Prevention and Interception of Chronic Degenerative Diseases and Cancer
Current Medicinal Chemistry Targeting AMPK Signaling Pathway to Overcome Drug Resistance for Cancer Therapy
Current Drug Targets Liposomes: An Emerging Approach for the Treatment of Cancer
Current Pharmaceutical Design Anti-Proliferative Role of the Tyrosine Kinase Inhibitors TKI-258 on Oral Squamous Cell Carcinoma In Vitro
Anti-Cancer Agents in Medicinal Chemistry Nanotherapeutics for the Treatment of Cancer and Arthritis
Current Drug Metabolism Pathobiology and Therapeutic Implications of Tumor Acidosis
Current Medicinal Chemistry